High impact for generic manufacturer Impax of first NDA for branded in-house drug
This article was originally published in Scrip
Impax Laboratories Inc. will find out in October whether its branded product division, Impax Pharmaceuticals, will be able to market its first novel drug developed in-house.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.